CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans.
Graft-versus-host disease (GVHD) occurs in an unpredictable fashion after 30% to 50% of matched-related transplantations. The presence of increased frequencies of CD4(+)CD25(+) regulatory T cells in donor grafts has been shown to ameliorate GVHD after allogeneic transplantation in murine models. To determine whether a similar relationship exists in humans, we quantitated the coexpression of CD25 on CD4(+) and CD8(+) T cells within 60 donor grafts infused into matched siblings and examined GVHD incidence in the respective recipients. Recipients in whom GVHD developed received donor grafts containing significantly higher frequencies of CD4(+) T cells coexpressing CD25 than those who did not (median, 9.26% vs 2.22%; P =.004). Frequencies of donor graft CD8(+) T cells coexpressing CD25 were also higher (0.65% vs 0.14%; P =.002). Furthermore, transplant recipients who received grafts containing fewer CD4(+)CD25(+) and CD8(+)CD25(+) T cells were less likely to acquire acute GVHD, even though these donor-recipient pairs were similar to others with respect to relevant clinical variables. These data suggest that the coexpression of CD4 and CD25 may be insufficient to identify regulatory T cells in humans and that increased frequencies and numbers of CD25(+) T cells in donor grafts is associated with GVHD in transplant recipients.
Stanzani
Marta
M
Transplant Immunology Laboratory, MD Anderson Cancer Center, SCRB 3.3019, 7455 Fannin St, Houston, TX 77030, USA.
Martins
Sergio L R
SL
Saliba
Rima M
RM
St John
Lisa S
LS
Bryan
Susan
S
Couriel
Daniel
D
McMannis
John
J
Champlin
Richard E
RE
Molldrem
Jeffrey J
JJ
Komanduri
Krishna V
KV
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology* / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D051379:Mice; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D012307:Risk Factors; D014184:Transplantation, Homologous
D015375:Receptors, Interleukin-2